6,659 reports of this reaction
5.4% of all TENOFOVIR DISOPROXIL FUMARATE reports
#8 most reported adverse reaction
RENAL FAILURE is the #8 most commonly reported adverse reaction for TENOFOVIR DISOPROXIL FUMARATE, manufactured by Gilead Sciences, Inc.. There are 6,659 FDA adverse event reports linking TENOFOVIR DISOPROXIL FUMARATE to RENAL FAILURE. This represents approximately 5.4% of all 123,510 adverse event reports for this drug.
TENOFOVIR DISOPROXIL FUMARATE has an overall safety score of 92 out of 100. Patients taking TENOFOVIR DISOPROXIL FUMARATE who experience renal failure should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
RENAL FAILURE is moderately reported among TENOFOVIR DISOPROXIL FUMARATE users, representing a notable but not dominant share of adverse events.
In addition to renal failure, the following adverse reactions have been reported for TENOFOVIR DISOPROXIL FUMARATE:
The following drugs have also been linked to renal failure in FDA adverse event reports:
RENAL FAILURE has been reported as an adverse event in 6,659 FDA reports for TENOFOVIR DISOPROXIL FUMARATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
RENAL FAILURE accounts for approximately 5.4% of all adverse event reports for TENOFOVIR DISOPROXIL FUMARATE, making it a notable side effect.
If you experience renal failure while taking TENOFOVIR DISOPROXIL FUMARATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.